Constant Therapeutics to begin phase II trial for COVID-19 therapy

By The Science Advisory Board staff writers

July 8, 2020 -- Constant Therapeutics' peptide drug TXA127 will advance to phase II clinical trials for the treatment of hospitalized COVID-19 patients.

The studies will be conducted in the U.S. (including the Brigham and Women's Hospital in Boston, MA), Italy (Policlinico S. Orsola-Malpighi Hospital in Bologna), and Israel (Bar-Ilan University and Technion Israel Institute of Technology). In total, over 400 patients are expected to be enrolled.

Previous preclinical studies have demonstrated that the active ingredient of the drug, angiotensin (Ang)-(1-7), supplements the loss of enzyme activity caused by SARS-CoV-2 binding to angiotensin-converting enzyme 2 (ACE2). By replacing the peptide with TXA127, the company hopes that it will provide protection and restore the ACE2/Ang-(1-7)/Mas axis.

The drug has also been shown to reduce fibrosis, stabilize endothelial and epithelial barrier function, and reduce inflammation in preclinical models of acute lung injury.

CSL Behring begins phase II study of COVID-19 therapy
CSL Behring has enrolled the first patient in its phase clinical II study to assess the safety and efficacy of CSL312 (garadacimab, factor XIIa-inhibitory...
GoldenBiotech moves COVID-19 drug to phase II
Golden Biotechnology (GoldenBiotech), a Taiwanese-based biopharmaceutical company, has received U.S. Food and Drug Administration approval to begin a...
RevImmune initiates phase II study for COVID-19 immunotherapy
RevImmune has launched a phase II clinical trial of CYT107 immune therapy for treatment of COVID-19 and is preparing to expand to the U.S.

Copyright © 2020 scienceboard.net


Register below for our weekly Letter from the Editor to receive the latest Science news and insights.
Email
Conferences
2020 ACCP Annual Meeting
September 20-22
Bethesda, Maryland United States
Bioprocess International West
September 21-24
Eastern Standard Time Zone (EST) United States
BioProcess International
September 21-24
Eastern Standard Time Zone (EST), Massachusetts United States
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter